Keating Financial Advisory Services’s Trevi Therapeutics TRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$29 Hold
2
– – ﹤0.01% 2548
2026
Q2
$37 Buy
2
+1
+100% +$15 ﹤0.01% 2539
2026
Q1
$12 Buy
+1
New +$11 ﹤0.01% 2539

Other funds holding TRVI

Keating Financial Advisory Services's TRVI Position: Q3 2026 in Review

Keating Financial Advisory Services held its Trevi Therapeutics (TRVI) position steady in Q3 2026 at 2 shares worth $29. The position accounts for ﹤0.01% of the portfolio, ranked #2548.

Keating Financial Advisory Services first reported a position in TRVI in Q1 2026 and has held it in 3 quarters since. The position peaked at $37 in Q2 2026. 223 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • Keating Financial Advisory Services held 2 shares of Trevi Therapeutics worth $29 as of Q3 2026.
  • Keating Financial Advisory Services left its Trevi Therapeutics share count unchanged in Q3 2026.
  • Trevi Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q3 2026, its #2548 holding.
  • Keating Financial Advisory Services first reported a position in Trevi Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's Trevi Therapeutics position peaked at $37 in Q2 2026.
  • 223 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on Keating Financial Advisory Services's 13F filing for Q3 2026, filed 12 Nov 2026.